Sold on shorter duration adjuvant HER2-targeted therapy for breast cancer? If by shorter you mean 6 months, then great. But the phase 3 SOLD trial indicates that 9 weeks of trastuzumab isn’t quite enough to achieve a non-inferior rate of disease free survival at 5 years (88%) when compared to the standard full year of treatment (91%). | Joensuu, JAMA Oncol 2018


Popular Posts